Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL ANTIHYPERTENSIVE DRUGS INDUSTRY
2.1 Summary about Antihypertensive Drugs Industry
2.2 Antihypertensive Drugs Market Trends
2.2.1 Antihypertensive Drugs Production & Consumption Trends
2.2.2 Antihypertensive Drugs Demand Structure Trends
2.3 Antihypertensive Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 ARB
4.2.2 CCB
4.2.3 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hypertension
4.3.2 PAH
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 ARB
5.2.2 CCB
5.2.3 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hypertension
5.3.2 PAH
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 ARB
6.2.2 CCB
6.2.3 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hypertension
6.3.2 PAH
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 ARB
7.2.2 CCB
7.2.3 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hypertension
7.3.2 PAH
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 ARB
8.2.2 CCB
8.2.3 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hypertension
8.3.2 PAH
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 ARB
9.2.2 CCB
9.2.3 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hypertension
9.3.2 PAH
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Novartis
10.1.2 Pfizer
10.1.3 Johnson & Johnson
10.1.4 Sanofi
10.1.5 Lupin
10.1.6 Ranbaxy Laboratories
10.1.7 Merck
10.1.8 Astra Zeneca
10.1.9 Daiichi Sankyo
10.1.10 Takeda
10.1.11 Actelion
10.1.12 United Therapeutics
10.2 Antihypertensive Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Novartis
10.2.2 Pfizer
10.2.3 Johnson & Johnson
10.2.4 Sanofi
10.2.5 Lupin
10.2.6 Ranbaxy Laboratories
10.2.7 Merck
10.2.8 Astra Zeneca
10.2.9 Daiichi Sankyo
10.2.10 Takeda
10.2.11 Actelion
10.2.12 United Therapeutics
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
